主页 > 医学文档 >
【drug-news】国王药厂表现出国王的身份
King Pharma: It Pays To Be King
Melanie Lindner, 01.08.08, 4:25 PM ET
CorePharma can relax as King Pharmaceuticals finally ended its patent lawsuit over muscle relaxant drug Skelaxin.
Shares of King Pharmaceuticals (nyse: KG - news - people ) skyrocketed Tuesday after the Bristol-Tenn.-based company filed with the Securities and Exchange Commission, stating that it signed a metaxalone 800 milligram product agreement on January 2. The deal allows CorePharma certain rights for a generic version of 800 mg Skelaxin.
King Pharmaceuticals gained 14.5%, or $1.51, to $11.89 in Tuesday afternoon trading.
Metaxalone, or Skelaxin as called by King Pharmaceuticals, is a muscle relaxant used to relieve pain caused by strains or sprains.
CorePharma was one of several bio-pharmaceutical firms to file with the Food and Drug Administration seeking permission to produce a generic version of Skelaxin. Eon Labs and Mutual Pharmaceutical also requested permission to make Skelaxin. On March 7, 2003, King filed suit against CorePharma, and later filed similar patent infringement suits against Eon and Mutual.
Only Core has been granted any rights to Skelaxin so far. Under the agreement King entered with Core on January 2 the latter signed a non-exclusive license to produce and market 400 milligram metaxalone, or generic Skelaxin. The license is slated to come into effect January 1, 2012.
Goldman Sachs analyst James Kelly originally expected generic competition for the drug to enter the market as early as 2009. While maintaining a "neutral" rating on King, Kelly says the firm's exclusive rights to Skelaxin through 2012 are worth $2.50 per share.
Morgan Stanley analyst Michael Rockefeller estimates that in 2008, Skelaxin will account for about $400.0 million in sales, or approximately 30.0% of King's total sales. 本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领 Market Scan
市场扫描
King Pharma: It Pays To Be King
国王药厂表现出国王身份
Melanie Lindner, 01.08.08, 4:25 PM ET
CorePharma can relax as King Pharmaceuticals finally ended its patent lawsuit over muscle relaxant drug Skelaxin.
核心药厂能轻松一下了，因为国王制药最终中止它关于肌松药美他沙酮的专利诉讼。
Shares of King Pharmaceuticals (nyse: KG - news - people ) skyrocketed Tuesday after the Bristol-Tenn.-based company filed with the Securities and Exchange Commission, stating that it signed a metaxalone 800 milligram product agreement on January 2. The deal allows CorePharma certain rights for a generic version of 800 mg Skelaxin.
星期二，当田纳西Bristol的公司向有价证券交易委员会发文，陈述它在1月2日签署了一个800毫克美他沙酮的产品协议后，国王制药的股票(nyse: KG - news - people )猛涨。该交易同意给予核心药业一定的权利生产非专利版本的800毫克的美他沙酮。
King Pharmaceuticals gained 14.5%, or $1.51, to $11.89 in Tuesday afternoon trading.
星期二的交易中，国王药业上涨14.5%，也就是1.51美元，收于11.89美元。
Metaxalone, or Skelaxin as called by King Pharmaceuticals, is a muscle relaxant used to relieve pain caused by strains or sprains.
Metaxalone或者国王药业称作的Skelaxin，是一种用于减轻由劳损或扭伤导致的疼痛的肌松药。
CorePharma was one of several bio-pharmaceutical firms to file with the Food and Drug Administration seeking permission to produce a generic version of Skelaxin. Eon Labs and Mutual Pharmaceutical also requested permission to make Skelaxin. On March 7, 2003, King filed suit against CorePharma, and later filed similar patent infringement suits against Eon and Mutual.
核心药业是向食品药品管理局发文以寻求允许生产非专利版本美他沙酮的几个生物制药公司中的一个。Eon Labs和 Mutual Pharmaceutical也寻求生产美他沙酮的许可。在2003年3月7日，国王向核心药业提出诉讼，而后也向Eon和 Mutual.提出了相似的专利侵权诉讼。
Only Core has been granted any rights to Skelaxin so far. Under the agreement King entered with Core on January 2 the latter signed a non-exclusive license to produce and market 400 milligram metaxalone, or generic Skelaxin. The license is slated to come into effect January 1, 2012.
到目前为止只有核心被授予了美他沙酮的所有权利。在1月2日国王和核心签署的协议下，随后签署了一个生产和销售400毫克美他沙酮，或者非专利的Skelaxin.的非排他性许可证。
Goldman Sachs analyst James Kelly originally expected generic competition for the drug to enter the market as early as 2009. While maintaining a "neutral" rating on King, Kelly says the firm's exclusive rights to Skelaxin through 2012 are worth $2.50 per share.
Goldman Sachs的分析家James Kelly起初预计关于药品进入市场的非专利竞争将持续到2009年早些时候。当国王维持一个中立地位时，Kelly说公司对美他沙酮的专有权到2012年值每股2.5美元。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-10-22 22:06
医学,生命科学网